不切、不燒、不照射——只用聲音
對付肝臟腫瘤，醫學界長期依賴三條路：手術切除、熱消融（射頻或微波）、放射治療。每一條都有代價——開刀的風險、熱損傷的不可控、放射線的累積毒性。對於腫瘤位置不適合手術的患者，這些選項更是大幅縮水。
2023 年 10 月，美國 FDA 開闢了第四條路。
Histotripsy：聲音作為手術刀
HistoSonics 開發的 Edison 系統採用一種叫做 Histotripsy（組織碎裂術） 的技術。原理是將聚焦超聲波精確打在腫瘤位置，在目標組織內產生受控的聲空化（acoustic cavitation）——也就是無數微型氣泡在極短時間內生成、膨脹、崩潰。這個物理過程在細胞層級產生巨大的機械剪切力，把腫瘤細胞撕碎、液化，而不涉及任何熱能。
這個區別很關鍵。熱消融的問題在於熱擴散難以精確控制，尤其在血管附近；Histotripsy 的機械作用高度局限在聚焦點，對周邊組織的附帶損傷更小。
更特別的是：Edison 系統能在治療過程中即時可視化組織被破壞的過程。這在任何現有腫瘤治療模式中都是獨一無二的——醫生不是在「估計」效果，而是在即時觀看腫瘤被消融。
臨床數據：HOPE4LIVER 試驗
FDA 的核准基礎是橫跨美國與歐洲 13 個中心的 HOPE4LIVER 臨床試驗，共評估 44 名患者、44 顆腫瘤：
- 技術成功率：95.5%
- 嚴重併發症率（CTCAE 3 級以上）：6.8%（30 天內 3 例）
- 患者組成：18 例肝細胞癌（HCC）、26 例肝轉移癌（來源包含結腸、直腸、乳房）
這個患者族群尤其值得注意——大多是腫瘤位置無法手術切除的病人，也就是在傳統選項上已經受限的那群人。對這類族群達到 95.5% 的技術成功率，數字本身說明了問題。
FDA De Novo：不只是審批，是建立新類別
FDA 透過 De Novo 分類程序核准 Edison 系統，這個細節值得多說兩句。De Novo 適用於市場上沒有類似前例的全新裝置——審查標準更嚴格，但通過後等於為這個技術類別建立了新的法規框架。
實際意義是：Edison 系統目前是美國唯一一台獲得核准的 Histotripsy 平台；未來競爭者若想進入這個市場，必須證明自己「實質等同」於 Edison，而 Edison 本身就是那個標竿。HistoSonics 用這場審批替自己蓋了一道先發優勢的護城河。
無針、無刀、快速恢復
實際操作上，患者躺在治療台上，Edison 系統的超音波探頭從體外對準腫瘤，全程無需任何穿刺或切口。治療後的液化組織會被身體自然吸收，治療部位的恢復速度比外科手術或熱消融都快。
HistoSonics 成立於 2001 年，源自密西根大學的研究，總部在明尼阿波利斯與安娜堡。肝臟是第一個核准適應症，公司目前正在將這項技術擴展到腎臟、胰腺等器官。
這意味著什麼
醫學史上，每一次新的物理手段被馴化成治療工具，都會為一批原本無路可走的患者打開一扇窗。X 光如此，放射治療如此，現在是聚焦超聲波。
Histotripsy 的物理機制不是新發現，但把它做成可以進手術室使用的系統、拿到監管機構的認可、並在真實患者身上驗證安全性，這是完全不同層次的工程。
95.5% 的成功率背後，是 44 個腫瘤、44 個人、和一個「這次或許有別的辦法」的可能性。
Sound Waves as a Scalpel: FDA Clears the First Histotripsy System for Liver Tumors
No Cutting, No Burning, No Radiation — Just Sound
Medicine has long relied on three main approaches against liver tumors: surgical resection, thermal ablation (radiofrequency or microwave), and radiation therapy. Each carries its own cost — the risks of open surgery, the imprecision of heat spread, the cumulative toxicity of radiation. For patients whose tumors sit in locations that make surgery impossible, these options narrow dramatically.
In October 2023, the FDA opened a fourth path.
Histotripsy: Sound as a Surgical Instrument
The Edison System, developed by HistoSonics, uses a technique called histotripsy. Focused ultrasound waves are directed precisely at the tumor, where they generate controlled acoustic cavitation — microscopic bubbles that form, expand, and collapse in microseconds. The mechanical shear forces produced at the point of focus destroy and liquefy tumor cells at a subcellular level, without any heat transfer.
That distinction matters. Thermal ablation struggles with heat diffusion, especially near blood vessels. Histotripsy’s mechanical action is confined tightly to the focal zone, reducing collateral damage to surrounding tissue.
What makes Edison uniquely remarkable is real-time visualization of tissue destruction as it happens. No other tumor ablation modality offers this. The physician isn’t estimating the effect — they are watching it occur.
The HOPE4LIVER Trial
FDA clearance rested on data from the HOPE4LIVER trial, conducted across 13 centers in the United States and Europe, evaluating 44 patients and 44 tumors:
- Technical success rate: 95.5%
- Serious adverse events (CTCAE Grade 3+): 6.8% (3 events within 30 days)
- Patient breakdown: 18 hepatocellular carcinoma (HCC), 26 liver metastases (from colorectal, breast, and other primaries)
The patient population is significant context. Most of these were patients with unresectable tumors — people for whom surgery was already off the table. Achieving a 95.5% technical success rate in that cohort is a meaningful result.
De Novo Authorization: More Than a Clearance
The FDA cleared Edison through the De Novo classification pathway, reserved for novel devices with no existing predicate. This isn’t a minor procedural distinction. De Novo clearance establishes Edison as the regulatory reference point for its entire device category — meaning any future competitor must prove substantial equivalence to Edison.
HistoSonics built a first-mover moat into the regulatory framework itself.
No Needles, No Incisions, Fast Recovery
In practice, the patient lies on a treatment table while Edison’s transducer is positioned externally over the tumor site. No punctures, no incisions. The liquefied tumor tissue is absorbed naturally by the body over time, and recovery is faster than surgical resection or thermal ablation.
HistoSonics was founded in 2001, originating from University of Michigan research, and is headquartered in Minneapolis and Ann Arbor. Liver tumors are the first approved indication; the company is extending the technology to kidneys, pancreas, and other organs.
What This Opens Up
Every time a new physical phenomenon has been harnessed into a clinical tool — X-rays, radiotherapy, focused ultrasound — it creates possibilities for patients who had none. The physics of histotripsy isn’t a new discovery. Engineering it into a system that can operate in a clinical setting, survive regulatory scrutiny, and demonstrate safety and efficacy in real patients — that is a different achievement entirely.
Behind the 95.5% technical success rate are 44 tumors, 44 patients, and 44 moments where “there might be another option” became something real.
參考來源：HistoSonics beams up FDA de novo nod for liver tumor-destroying ultrasound — FierceBiotech
發佈留言